References
- Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. [Internet]. Lyon, France: International Agency for Research on Cancer 2013. [Citated 2015 Sep 30] Available at: http://globocan.iarc.fr
- D’Addario G, Früh M, Reck M, Baumann P, Klepetko W, Felip E. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v116-9.
- Vansteenkiste J, Ruysscher D De, Eberhardt WEE, Lim E, Senan S, Felip E, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 (Suppl 6): vi89-98.
- Cufer T, Ovcaricek T, O’Brien MER. Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur J Cancer 2013; 49: 1216-25.
- Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53: 2231-47.
- Albini A, Pennesi G, Donatelli F, Cammarota R, Flora S De, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardiooncological prevention. J Natl Cancer Inst 2010; 102: 14-25.
- Vejpongsa P, Yeh ETH. Prevention of anthracycline-induced cardiotoxicity. J Am Coll Cardiol 2014; 64: 938-45.
- Lainscak M, Haehling S von, Anker SD. Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers. Int J Cardiol 2009; 132: 303-11.
- Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749-54.
- Weaver KE, Foraker RE, Alfano CM, Rowland JH, Arora NK, Bellizzi KM, et al. Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care? J Cancer Surviv 2013; 7: 253-61.
- Patanè S. Cardiotoxicity: Cisplatin and long-term cancer survivors. Int J Cardiol 2014; 175: 201-2.
- Bano N, Najam R, Qazi F. Adverse cardiac manifestations of cisplatin – a review. Int J Pharm Sci Rev Res 2013; 18: 80-5.
- Khan S, Chen CL, Brady MS, Parameswaran R, Moore R, Hassoun H, et al. Unstable angina associated with cisplatin and carboplatin in a patient with advanced melanoma. J Clin Oncol 2012; 30: e163-4.
- Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE, et al. High incidence of thromboembolic events in patients treated with cisplatinbased chemotherapy: a large retrospective analysis. J Clin Oncol 2011; 29: 3466-73.
- Demkow U, Stelmaszczyk-Emmel A. Cardiotoxicity of cisplatin-based chemotherapy in advanced non-small cell lung cancer patients. Respir Physiol Neurobiol 2013; 187: 64-7.
- El-Awady E-SE, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatininduced cardiotoxicity: mechanisms and cardioprotective strategies. Eur J Pharmacol 2011; 650: 335-41.
- Hussein A, Ahmed AAE, Shouman SA, Sharawy S. Ameliorating effect of DL-α-lipoic acid against cisplatin-induced nephrotoxicity and cardiotoxicity in experimental animals. Drug Discov Ther 2012; 6: 147-56.
- Schinkel LD van, Willemse PM, Meer RW van der, Burggraaf J, Elderen SGC van, Smit JWA, et al. Chemotherapy for testicular cancer induces acute alterations in diastolic heart function. Br J Cancer 2013; 109: 891-6.
- Strumberg D, Brugge S, Korn MW, Koeppen S, Ranft J, Scheiber G, et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002; 13: 229-36.
- Altena R, Hummel YM, Nuver J, Smit a J, Lefrandt JD, Boer R a de, et al. Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer. Ann Oncol 2011; 22: 2286-93.
- Hardy D, Liu C-C, Cormier JN, Xia R, Du XL. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Ann Oncol 2010; 21: 1825-33.
- Wachters FM, Graaf WTA Van Der, Groen HJM. Cardiotoxicity in advanced non-small cell lung cancer patients treated with platinum and non-platinum based combinations as first-line treatment. Anticancer Res 2004; 24: 2079- 83.
- Lang RM, Bierig M, Devereux RB, Flachskampf F, Foster E, Pellikka P, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006; 7: 79-108.
- Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth O A, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10: 165-93.
- Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-21.
- Meinardi BMT, Gietema JA, Veldhuisen DJ Van, Runne MA, Sluiter WJ, Mulder NH, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725-32.
- S. Gillespie H, J. McGann C, D. Wilson B. Noninvasive diagnosis of chemotherapy related cardiotoxicity. Curr Cardiol Rev 2012; 7: 234-44.
- Daniels LB, Laughlin GA, Clopton P, Maisel AS, Barrett-Connor E. Minimally elevated cardiac troponin T and elevated N-terminal pro-B-type natriuretic peptide predict mortality in older adults: results from the Rancho Bernardo Study. J Am Coll Cardiol 2008; 52: 450-9.
- Gharib MI, Burnett a K. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 2002; 4: 235-42.
- Eschenhagen T, Force T, Ewer MS, Keulenaer GW de, Suter TM, Anker SD, et al. Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2011; 13: 1-10.
- Patil H, Vaidya O, Bogart D. A review of causes and systemic approach to cardiac troponin elevation. Clin Cardiol 2011; 34: 723-8.